Neurolambda Therapeutics Inc. has disclosed new non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of cancer, systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis.
Researchers from the University of Copenhagen and collaborating institutions aimed to develop a therapy for chronic neuropathic pain based on gene therapy delivered with adeno-associated viral (AAV) vectors.
Korean researchers reported the discovery and preclinical characterization of KSI-028, a novel tetrahydroquinoline-based STING inhibitor with activity across multiple models of STING activation.
Aeovian Pharmaceuticals Inc. has divulged new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma, vascular disorders, Duchenne muscular dystrophy, liver and metabolic diseases, among others.
Boehringer Ingelheim Pharma GmbH & Co. KG and Immunitas Therapeutics Inc. have signed a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases.
AOP Orphan Pharmaceuticals GmbH (AOP Health) has established a strategic partnership with VRG Therapeutics Zrt to advance a novel Kv1.3 potassium channel inhibitor for use in inflammation and immunology indications.
A team at the Korea Research Institute of Chemical Technology has synthesized tetrahydroisoquinoline- or isoindoline-substituted [1,2,4]triazolo[1,5-a]pyridine derivatives acting as tyrosine-protein kinase JAK1 inhibitors.
The classic origin story for a biotech startup is that of a scientist who nurtures his work out of a university and to commercial success. For Link Biologics Ltd. and its TSG6-based pipeline, the story is the other way around; it began with now-CEO Reuben Dawkins meeting University of Manchester scientists Tony Day and Caroline Milner while he was on the lookout for “great science that needs help to make it to patients.” The three are now co-founders of Link, which spun out of the University of Manchester in 2021 and has four programs in three indications, all based on TSG-6 biology.
Evotec SE has announced the nomination of a small-molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall SA. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need. The collaboration, established in 2022, leverages Evotec’s fully integrated, AI/machine learning enhanced discovery and preclinical development platforms.
Ono Pharmaceutical Co. Ltd. has synthesized bridged bicyclic compounds acting as endosomal/lysosomal proton channel TMEM175 activators. As such, they are described as potentially useful for the treatment of inflammatory disorders, lysosomal storage diseases, autoimmune disease and Parkinson’s disease.
RSS
